AbCellera Biologics (ABCL) Gross Profit: 2020-2023
Historic Gross Profit for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2023 value amounting to $6.1 million.
- AbCellera Biologics' Gross Profit fell 69.62% to $6.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $23.8 million, marking a year-over-year decrease of 94.31%. This contributed to the annual value of $16.1 million for FY2024, which is 32.67% down from last year.
- As of Q4 2023, AbCellera Biologics' Gross Profit stood at $6.1 million, which was up 94.16% from $3.1 million recorded in Q3 2023.
- AbCellera Biologics' 5-year Gross Profit high stood at $271.9 million for Q1 2022, and its period low was $3.1 million during Q3 2023.
- In the last 3 years, AbCellera Biologics' Gross Profit had a median value of $22.0 million in 2021 and averaged $64.3 million.
- Its Gross Profit has fluctuated over the past 5 years, first spiked by 4,230.12% in 2021, then slumped by 96.90% in 2023.
- Quarterly analysis of 4 years shows AbCellera Biologics' Gross Profit stood at $182.4 million in 2020, then crashed by 35.61% to $117.4 million in 2021, then tumbled by 82.96% to $20.0 million in 2022, then plummeted by 69.62% to $6.1 million in 2023.
- Its Gross Profit stands at $6.1 million for Q4 2023, versus $3.1 million for Q3 2023 and $6.2 million for Q2 2023.